The planned test will be based on LifeCodexx's methylation-specific quantitative PCR technology.
The UK-based firm is selling technology underlying its point-of-care molecular diagnostics platform, the Enigma MiniLab.
The firm has immediate access to $800,000 in previously restricted cash, and an additional $10.8 million in capital through new convertible notes.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
Curetis' new subsidiary will focus on using a recently acquired database of bacterial genome sequences to identify novel antibiotic resistance markers.
While point-of-care molecular testing of patients with respiratory illness wasn't associated with lower antibiotic use, patients tested had shorter drug courses.
The deal covers Mobidiag's full line of Amplidiag tests for gastrointestinal infections, as well as the high-throughput Amplidiag Easy system.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The test adds to the firm's current portfolio of 30 infectious disease and oncology tests that use its Sentosa PCR and NGS workflow.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The test, which runs directly from a patient nasopharyngeal swab, is the fifth assay on the firm's sample-to-result molecular diagnostics platform.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.
At the German Society of Human Genetics annual meeting in Bochum, Berlin's Atlas Biolabs talked about its first experience with the Clarigo test.
Codexis has been using its CodeEvolver platform to engineer high-performance enzymes for next-generation sequencing and PCR for in vitro diagnostics.
The test runs on Qiagen's Rotor-Gene Q MDx system and is designed to qualitatively detect the JAK2 V617F/G1849T allele in genomic DNA from whole blood.
The company plans to launch its PlexWell kit to enable multiplexing of 384 samples for NGS library construction in the second quarter of this year.
The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.
The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.
The semifinalists will receive $50,000 each to develop prototypes of their concepts for submission in the second phase of the challenge.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.